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We have previously found that uremic human serum
upregulates RUNX2 in vascular smooth muscle cells (VSMCs),
and that RUNX2 is upregulated in areas of vascular
calcification in vivo. To confirm the role of RUNX2, we
transiently transfected a dominant-negative RUNX2
(DRUNX2) construct in bovine vascular smooth muscle cells
(BVSMCs). Blocking RUNX2 transcriptional activity
significantly decreased uremic serum induced alkaline
phosphatase (ALP) activity (268734 vs 18879.5 U/g protein,
Po0.05) and osteocalcin expression (172717 vs 12579
ODU, Po0.05). To determine the mechanism by which
uremic serum upregulates RUNX2, we examined cell
signaling pathways. BVSMCs were incubated in the presence
or absence of inhibitors and RUNX2 expression and ALP
activity were determined. The results demonstrate that
the cyclic AMP (cAMP)/protein kinase A (PKA), but not
protein kinase C, signaling pathway is involved in uremic
serum-induced RUNX2 expression and ALP activity in
BVSMCs. To examine potential uremic ‘toxins’, we measured
bone morphogenetic protein (BMP)-2 concentration and
found that uremic serum contained increased BMP-2 (uremic
serum¼ 169733 pg/ml, normal serum¼ 117715 pg/ml,
Po0.05). The incubation of BVSMCs with noggin, an inhibitor
of BMP, decreased RUNX2 expression. In addition, BMP-2
secretion progressively increased during calcification and
uremic serum enhanced its secretion compared to normal
serum. In conclusion, this study demonstrates that RUNX2
transcriptional activity is critical in uremic serum-induced
bone matrix protein expression in BVSMCs and that the
cAMP/PKA pathway is involved. BMP-2 is also increased in
uremic serum and can upregulate RUNX2 and calcification
in vitro in VSMCs.
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Cardiovascular disease and stroke are the leading causes of
death in patients on dialysis, at a risk that is 10–20-fold the
age- and sex-matched general population.1 Vascular calcifica-
tion, in both the intima and media, is also more prevalent
and severe in patients with chronic kidney disease (CKD),
and is associated with increased morbidity and mortality
(reviewed by Moe and Chen2). For many years, vascular
calcification in CKD patients was thought to occur
predominantly by unregulated, purely physiochemical me-
chanisms, as disorders of bone and mineral metabolism are
common in CKD. However, recent data demonstrate that
vascular calcification in CKD patients is a regulated process.
Important work in the 1990s demonstrated the presence
of bone proteins in areas of calcification in pathologic
specimens from both coronary and peripheral arteries.3–7
Furthermore, it was demonstrated that vascular smooth
muscle cells (VSMCs) isolated from human or bovine arteries
were capable of mineralizing in vitro3,8 in a similar manner to
osteoblasts.9 We have confirmed these findings in arteries
from dialysis patients, demonstrating the presence of ‘bone’
proteins such as osteopontin, bone sialoprotein, type I
collagen, and alkaline phosphatase (ALP), and even an
osteoclast-like cell, in arteries from patients with CKD.10–12
These data confirm a cell-mediated, osteogenic process in
vascular calcification in CKD patients on dialysis, similar to
that in non-CKD patients, and suggest that VSMCs can
phenotypically behave like osteoblasts.
Mesenchymal stem cells are capable of differentiating into
osteoblasts, chondrocytes, adipocytes, and myoblast/smooth
muscle cells by expression of one set of transcription factors
and repression of another. Selective deletion of RUNX2 in
mice leads to a failure to form mineralized bone by either
endochondral or intramembranous ossification,13–15 con-
firming the critical role of RUNX2 in osteoblast differentia-
tion. One of the initial markers of osteoblast differentiation
is the upregulation of RUNX2 followed by the expression
of matrix proteins, and then mineralization, the former
considered the best marker of the differentiated osteoblast.
In addition to RUNX2, bone morphogenic proteins are
also important early in mineralization and are known to
upregulate RUNX2 expression.15,16 Exogenous bone morpho-
genetic protein (BMP)-2 implanted into animals can induce
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extraskeletal calcification.17 However, there are several BMPs
with some redundancy in activity such that targeted deletions
of single BMPs does not cause phenotypic alterations in bone
mineralization.
Jono et al.18 first demonstrated that exogenous phosphate
induced the expression of RUNX2 and calcification of human
VSMCs. We have also demonstrated that the expression of
RUNX2 and its downstream proteins osteopontin and type I
collagen was found in both the medial and intimal layer of
calcified arteries obtained from patients undergoing renal
transplantation.19 Similar findings were observed in arteries
from non-CKD patients.20 Furthermore, pooled serum from
patients undergoing dialysis (uremic serum) upregulated
RUNX2 and its downstream proteins osteopontin and
ALP activity in bovine vascular smooth muscle cells
(BVSMCs) compared to serum from non-CKD (normal)
individuals,19,21 regardless of the phosphorus concentration.
Uremic human serum also leads to accelerated and increased
calcification in BVSMCs in vitro compared to normal
serum.21 Taken together, these findings suggest that RUNX2
may be a key regulatory factor in the vascular calcification
of CKD, with VSMCs transforming to osteoblast-like cells in
response to uremic toxins. There are many potential uremic
toxins that, individually, have been shown to induce
calcification in vitro such as oxidized proteins, phosphorus,
lipids, parathyroid hormone-related peptide, and calcitriol
(reviewed by Moe and Chen2). However, it is most likely that
a combination of factors in uremic serum is responsible for
the upregulation of RUNX2. The purpose of the present
study was to (1) confirm the direct role of RUNX2 in bone
matrix protein expression, (2) determine the cell signaling
mechanism by which uremic serum upregulates RUNX2 in
BVSMCs, and (3) examine the role of bone morphogenic
proteins in the upregulation of RUNX2.
RESULTS
Role of RUNX2 in uremic serum-induced ‘bone’ protein
expression from BVSMCs
As detailed in the Materials and Methods, this RUNX2 DNA-
binding domain (DRUNX2) has been well characterized by
Ducy et al.22 and has no transactivation ability on its own.
We first examined ALP activity in dominant-negative
RUNX2 (DRUNX2) transiently transfected or empty vector
and non-transfected (control) BVSMCs treated with human
normal or uremic serum for 72 h. As shown in Figure 1a,
uremic serum significantly increased ALP activity in non-
transfected BVSMCs compared to normal serum (normal-
134710 U/g protein; uremic¼ 268734 U/g protein,
Po0.05). Transient transfection with DRUNX2 significantly
decreased uremic serum-induced ALP activity in BVSMCs
(268734 vs 18879.5 U/g protein, Po0.05), but had no
effect on cells treated with normal serum (Figure 1a).
Transfection with the empty vector control (pEFBOS) had
no effect on ALP activity in BVSMCs treated with normal or
uremic serum (Figure 1a). Furthermore, uremic serum, but
not normal serum, significantly increased the expression of
the osteoblast marker osteocalcin, whereas DRUNX2 trans-
fection significantly reduced uremic serum-induced osteo-
calcin expression in BVSMCs (Figure 1b). In contrast,
transfection with the empty vector had no significant effect
on osteocalcin expression in BVSMCs treated with normal or
uremic serum (Figure 1b). These results suggest that RUNX2
is critical for uremic serum-induced transformation of
BVSMCs to osteoblast-like cells, capable of expression of
‘bone’ proteins.
Cell signaling pathways
To examine the potential signaling mechanism involved in
uremic serum-induced expression of RUNX2 and ALP
activity in BVSMCs, cells were treated with normal or
uremic serum in the presence or absence of protein kinase A
(PKA) inhibitor KT5720 (10 mmol/l), an inhibitor of cyclic
AMP (cAMP) production SQ22536 (500 nmol/l), or protein
kinase C (PKC) inhibitor GF10923X. Uremic serum sig-
nificantly increased RUNX2 expression by 85% in BVSMCs
at 48 h. Inhibition of PKA activity by KT5270 blocked uremic
serum-induced RUNX2 expression (Po0.05; Figure 2a),
but had no effect on BVSMCs treated with normal serum
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Figure 1 | ALP activity and osteocalcin expression in BVSMCs
treated with normal or uremic serum after transient transfection
with the dominant-negative RUNX2 (DRUNX2) construct. (a) ALP
activity and (b) osteocalcin expression in BVSMCs treated with normal
or uremic serum after transient transfection with the dominant-
negative RUNX2 (DRUNX2) construct. BVSMCs were transfected with
a dominant-negative RUNX2 or with pEF-BOS empty vector as a
negative control. After transfection, cells were incubated in the
presence of 10% normal serum or uremic serum for 72 h. Cellular
proteins were solubilized and supernatants were assayed for ALP
activity normalized to (a) cellular protein content or (b) osteocalcin
expression by Western blotting. Data are shown as mean7s.d. from
three experiments. Non-T: non-transfected; T: transfected; EV: empty
vector. *Po0.05, uremic vs normal; #Po0.05, uremic/NT vs uremic/T.
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(Figure 2a). Blockade of PKA also abolished uremic serum-
induced ALP activity (Figure 2b). Similar results were
obtained with inhibitor of cAMP production by SQ22536
(data not shown). In contrast, inhibition of PKC activity by
GF10923X had no effect on uremic serum-induced upregula-
tion of RUNX2 and ALP activity in BVSMCs (Figure 3).
Role of BMP-2 in uremic serum-induced RUNX2 expression
and calcification in BVSMCs
Because BMP-2 is known to upregulate RUNX2, we
examined the potential role of BMP-2 in uremic serum-
induced RUNX2 expression and calcification in BVSMCs.
First, we measured the BMP-2 levels in human serum and
found that the concentration of BMP-2 was significantly
higher in pooled uremic serum than in normal human serum
(uremic serum¼ 169733 pg/ml, pooled from 15 different
samples; normal serum¼ 117715 pg/ml, pooled from 14
different samples; Po0.05). We then incubated BVSMCs for
48 h with normal or uremic serum in the presence or absence
of 1 mg/ml noggin, which prevents BMP-2, -4, and -7 binding
to their receptors. As expected, uremic serum increased
RUNX2 expression in BVSMCs compared to normal serum,
but inhibition of BMP binding to its receptor by noggin
significantly decreased uremic serum-induced RUNX2 ex-
pression in BVSMCs (Figure 4; 3574.5 (uremic) vs 2273.5
(uremic/noggin), Po0.05). However, noggin had no effect
on RUNX2 expression in BVSMCs treated with normal
serum (Figure 4; 2076.0 (normal) vs 1973.8 (normal/
noggin)).
To better understand the potential contribution of
elevated BMP-2 levels in uremia, we measured the BMP-2
in 39 stored pre-dialysis serum samples from individual
dialysis patients. The range of serum BMP-2 concentrations
was from to 19 to 365 pg/ml, with a median value of 86 pg/
ml. There was no significant correlation between BMP-2
levels and gender, age, parathyroid hormone (PTH), calcium,
phosphorus, or albumin levels. We then evaluated the change
in BMP-2 concentrations over time in 10 individual dialysis
patients at monthly intervals over 3 months. The data
demonstrate a large variability in serum BMP-2 levels over
time (Figure 5). Of importance, the pooled serum was
collected from anuric patients, which may explain why our
pooled serum had a higher concentration than the median of
the individual samples. To our knowledge, this is the first
report of serum BMP-2 levels from dialysis patients. The
finding of variability between and among patients suggests
that multiple factors may affect serum BMP-2 levels in
0
10
20
30
40
50
60
70
80
R
UN
X2
/
-
a
ct
in
 (%
)
-Actin
Normal Normal
+KT5720
Uremic Uremic
+KT5720
Normal Normal
+KT5720
Uremic Uremic
+KT5720
*
a
#
*
#
RUNX2
0
20
40
60
80
100
AL
P 
ac
tiv
ity
 (U
/g 
pro
tei
n)
b
Figure 2 | RUNX2 expression and ALP activity in BVSMCs treated
with normal or uremic serum in the presence or absence of PKA
inhibitor (KT5720). (a) RUNX2 expression and (b) ALP activity in
BVSMCs treated with normal or uremic serum in the presence or
absence of PKA inhibitor (KT5720). Cells were incubated in the
presence of 10% normal serum or uremic serum with or without
10mmol/l KT5720 (a specific inhibitor of PKA) for 48 h (RUNX2) or 72 h
(ALP activity). (a) Total RNA was isolated and RUNX2 RT-PCR was
performed using b-actin as an internal control, and the ratio
determined. (b) Cellular proteins were solubilized and supernatants
were assayed for ALP activity normalized to cellular protein content.
Data are shown as mean7s.d. from three to four experiments.
*Po0.05, uremic vs normal; #Po0.05, uremic vs uremicþ KT5720.
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Figure 3 | RUNX2 expression and ALP activity in BVSMCs treated
with normal or uremic serum in the presence or absence of PKC
inhibitor (GF10923X). (a) RUNX2 expression and (b) ALP activity in
BVSMCs treated with normal or uremic serum in the presence or
absence of PKC inhibitor (GF10923X). Cells were incubated in the
presence of 10% normal serum or uremic serum with or without
10mmol/l GF10923X (a specific inhibitor of PKC) for 48 h (RUNX2
expression) or 72 h (ALP activity). (a) Total RNA was isolated and
RUNX2 RT-PCR was performed using b-actin as an internal control,
and the ratio determined. (b) Cellular proteins were solubilized and
supernatants were assayed for ALP activity normalized to cellular
protein content. Data are shown as mean7s.d. from three to four
experiments. *Po0.05, uremic vs normal.
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dialysis patients, including the degree of residual renal
function. To determine if BMP-2 secretion contributes to
uremic serum-induced calcification in BVSMCs, cells were
incubated with normal or uremic serum in the presence of
calcification media, and BMP-2 levels were examined by
enzyme-linked immunosorbent assay on days 3, 7, 11, and
14. The result demonstrated a progressive increase in BMP-2
secretion into the media over time during calcification
(Figure 6; Po0.05). Furthermore, compared to normal
serum, uremic serum significantly increased BMP-2 secretion
in BVSMCs during each time point of mineralization
(Figure 6; Po0.05). In addition, the uremic serum-induced
increased BMP-2 secretion is associated with enhanced
calcification in BVSMCs (uremic¼ 3.670.54 mmol/mg, nor-
mal¼ 2.670.46 mmol/mg, day 7, Po0.05; uremic¼ 5.67
0.71 mmol/mg, normal¼ 4.270.78 mmol/mg, day 14,
Po0.05). To confirm that this increase in BMP-2 production
may directly impact uremic-induced calcification, BVSMCs
were incubated with calcification media in the presence or
absence of recombinant human BMP-2 (500 ng/ml) for 7 and
14 days, and calcification was examined. The results
demonstrated that BMP-2 significantly increased calcification
in BVSMCs on both day 7 and 14 (Figure 7; 1.2870.5 vs
2.0570.12 mmol/mg, Po0.05, day 7; 3.5670.18 vs
5.1370.74 mmol/mg, Po0.05, day 14). However, incubation
with noggin failed to inhibit calcification in BVSMCs
incubated with normal serum, uremic serum, or fetal
bovine serum. Furthermore, noggin did not inhibit the
calcification of BVSMCs treated with exogenous BMP-2 (data
not shown), suggesting that it is ineffective in the inhibition
of BMP-2-induced calcification. Thus, although noggin has
short-term inhibitory effects on RUNX2 expression, noggin
does not inhibit calcification in BVSMCs in long-term (14
days) cultures. Thus, both in vivo and in vitro data suggest
a potential important role of BMP-2 in uremic vascular
calcification.
DISCUSSION
We have previously demonstrated that uremic serum induces
mineralization of BVSMCs independent of phosphorus, with
upregulation of RUNX2, and that RUNX2 is expressed in
calcified arteries from CKD patients.21 Vascular calcification
is more common in patients with uremia, and increases
with duration of dialysis, an imperfect treatment to remove
uremic toxins. Many such toxins have been individually
examined in VSMC culture and have been found to induce
calcification, including elevated phosphorus,18 PTH and
PTH-related peptide,23 calcitriol,24 advanced glycation end
products,25 alterations of lipoproteins,26–28 and homo-
cysteine.29 However, it is more likely that combinations of
such factors are more potent than any individual factor. Rather
than focusing on a single toxin, we have utilized pooled
uremic serum as a surrogate for the uremic mileau, and
examined cell signaling mechanisms that affect RUNX2 and
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Figure 4 | RT-PCR analysis of the expression of RUNX2 in BVSMCs
in the presence or absence of an inhibitor of BMP. BVSMCs were
incubated with normal or uremic serum in the presence or absence
of 1 mg/ml of noggin, a specific inhibitor of BMP binding to its
receptor, for 48 h. Total RNA was isolated and the expression of
RUNX2 was determined by RT-PCR. b-Actin was used as an internal
control and the ratio determined. Data are shown as mean7s.d. from
three experiments. *Po0.05, uremic vs normal.
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Figure 5 | BMP-2 serum concentrations in individual dialysis
patients over a 3-month period. Serum was collected from 10
individual dialysis patients at monthly intervals over 3 months (days
1, 30, 60, and 90) and BMP-2 concentrations were determined by
enzyme-linked immunosorbent assay. Each symbol/line represents
a different patient. The results show a large variability in BMP-2
levels over time.
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Figure 6 | BMP-2 secretion from BVSMCs treated with normal
or uremic serum during calcification. BVSMCs were incubated
with calcification media (10 mmol/l b-glycerophosphate, 107 mol/l
insulin, and 50 mg/ml ascorbic acid) in the presence of either
15% normal or uremic serum for up to 14 days. Conditioned media
from BVSMC cultures were collected and BMP-2 measured by the
enzyme-linked immunosorbent assay kit. The preincubation levels
of BMP-2 were subtracted from post-incubation levels. Data are
shown as mean7s.d. from three experiments. *Po0.05, uremic
vs normal at each time point; Po0.05 for progression of BMP-2
secretion over time.
Kidney International (2006) 70, 1046–1053 1049
NX Chen et al.: Uremia and vascular calcification o r i g i n a l a r t i c l e
one uremic toxin that is known to upregulate RUNX2. Our
results confirm the importance of RUNX2 and demonstrate
that the upregulation of RUNX2 in BVSMCs by uremic
serum is mediated by the cAMP/PKA, but not PKC, signaling
pathway, and that BMP-2 is an important uremic toxin
that upregulates RUNX2 and may initiate calcification in
BVSMCs.
Our data confirm that RUNX2 transcriptional activity is
important in uremic serum-induced expression of ‘bone’
proteins in BVSMCs, as transient transfection of a dominant-
negative RUNX2 transcript (DRUNX2) reduced uremic
serum-induced ALP activity and osteocalcin expression in
BVSMCs to levels in cells incubated in normal serum. This
suggests that RUNX2 is critical for uremic serum-induced
transdifferentiation of BVSMCs to osteoblast-like cells that
can express bone proteins. However, DRUNX2 did not affect
ALP activity or osteocalcin expression in normal serum-
treated BVSMCs, indicating that additional factors must also
regulate RUNX2. The requirement for RUNX2 in osteoblast
differentiation is well documented by the experimental
finding that RUNX2 knockout mice are completely devoid
of mature osteoblasts and mineralized bone.13–15 In addition,
overexpression of RUNX2 in non-osteogenic cells such as
C3H10T1/2 cells,15 primary bone marrow stromal cells,30 and
skin fibroblasts31 leads to mineralization in vitro.
A potential role of RUNX2 in the pathogenesis of vascular
calcification was initially suggested by evidence in BVSMCs
that phosphorus upregulates RUNX2 and expression is
increased during mineralization.18 In addition, Steitz
et al.32 demonstrated that human VSMCs incubated in
calcification media progressively lost smooth muscle markers,
and had progressive increase in RUNX2 expression during
calcification. Furthermore, in areas of arterial calcification in
the matrix gla/ mice, RUNX2 is progressively increased.32
In BVSMCs, serum from dialysis patients, compared to
normal serum, increased the expression of RUNX2 and
increased and accelerated calcification.19,21 In vivo, we have
demonstrated that RUNX2 was present in both the media
and the intima in calcified vessels (but not non-calcified
arteries) from CKD patients, and this expression corre-
sponded with immunostaining for its downstream proteins
osteopontin and type I collagen.19 Tyson et al.20 observed
similar findings in non-CKD patients. In the present study,
the importance of RUNX2 in uremic serum-induced cell
phenotypic change was validated by our results demonstrat-
ing that blockade of RUNX2 transcriptional activity by
transfection of a dominant-negative construct in BVSMCs
can inhibit uremic serum-induced osteocalcin expression and
ALP activity. The ultimate test would be to determine if
blocking RUNX2 activity can reduce mineralization in vitro
in BVSMCs. Although we attempted such experiments, stable
transfection of this construct using antibiotic G418 selection
method produced significant alterations in cell growth
compared to non-transfected cells and transiently transfected
cells, which in turn affects cell density and mineralization.
Alternative transfection methods are currently under in-
vestigation. Nonetheless, our data and that of others clearly
support an important role of RUNX2 in the pathogenesis of
vascular calcification.
The results also demonstrated that cAMP/PKA is
important in uremic serum upregulation of RUNX2. These
findings are similar to the work of Tintut et al.33 demonstrat-
ing that increased cAMP is involved in tumor necrosis factor-
a increased RUNX2 activity in calcifying VSMCs. Thus, our
pooled uremic serum may be reflective of inflammation, a
common finding during dialysis.34 Indeed, several recent
studies have identified inflammation with elevations in
C-reactive protein as important in the pathogenesis of vascular
calcification. Oh et al.35 found that elevations of C-reactive
protein were strongly associated with increased vascular
calcification in young adults, and Stompor et al.36 found that
patients with higher levels of interleukin-6 and C-reactive
protein had greater coronary artery calcification. The cAMP/
PKA pathway is also a prominent cell signaling pathway of
PTH upregulation of RUNX2,37 with resulting anabolic
effects of PTH on osteoblasts. Clearly, the pooled uremic
serum had higher PTH levels than normal serum. However,
the role of PTH in vascular calcification is controversial. Jono
et al.23 found that high concentrations of PTH and PTH-
related peptide inhibited vascular calcification. Clinical
studies generally find that a low or very high level of PTH
leads to increased vascular calcification.38,39 Thus, further
studies are required to determine precisely what uremic
toxins may upregulate RUNX2 via cAMP/PKA.
BMP-2 is another potential ‘uremic toxin’, as we found
increased levels in uremic compared to normal human serum
and that serum concentrations fluctuate in individual
patients. This study also demonstrated that noggin, an
inhibitor of BMPs, can inhibit uremic serum-induced
RUNX2 expression in short-term experiments. Furthermore,
BMP-2 secretion progressively increased in BVSMCs during
mineralization and uremic serum enhanced its secretion. The
concentration of BMP-2 in our pooled human uremic serum
was 169 pg/ml, with a final concentration in the cultures of
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Figure 7 | The effect of BMP-2 in calcification of BVSMCs. BVSMCs
were treated with or without recombinant human BMP-2 (500 ng/ml)
in the presence of calcification media (10 mmol/l b-glyceropho-
sphate, 107 mol/l insulin, and 50 mg/ml ascorbic acid) with 15% fetal
bovine serum for 7 and 14 days, and calcium deposition measured.
Data are shown as mean7s.d. from three experiments. *Po0.05,
BMP-2 treatment vs control, same day; #Po0.05, day 14 vs day 7,
same treatment.
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25 pg/ml after dilution of the serum to 15%. In contrast, the
concentration of secreted BMP-2 is over 2000 pg/ml, or 80-
fold greater. Thus, there is likely additive effects of the BMP-2
from the uremic serum and the secreted BMP-2 from the
calcifying BVSMCs. It is not clear what factor or factors in
the uremic serum induce the secretion of BMP-2 from the
BVSMCs. The importance of BMP-2 is not surprising, as it is
a potent osteo-inductive factor in mesenchymal stem cells
and marrow stromal cells,40 and BMP-2 has been detected in
human calcified arteries41 and in pericytes.3 Bostrom and co-
workers have demonstrated that BMP-2 increased calcifica-
tion and osteogenic differentiation in calcifying VSMCs.16
BMP-2 is known to upregulate RUNX2 in osteoblasts and
pericytes.15,16
Unfortunately, we were unable to demonstrate an effect of
noggin on calcification in cultured BVSMCs, even in cultures
in which BMP-2 was added. There are several possible
explanations. First, the calcification experiments require
long-term cultures and the inhibitory effect of noggin may
not be effective chronically. Second, noggin not only impairs
BMP-2 binding but also other BMPs. Recent data have
demonstrated that BMP-7 can directly inhibit vascular
calcification (Mathew et al., 2005 ASN abstract, F-FC064).
Thus, noggin may simultaneously inhibit the promineralizing
effect of BMP-2 and the anti-mineralizing effect of BMP-7,
resulting in no net effect on calcification. Third, the addition
of exogenous noggin may not affect endogenously produced
BMP-2 effects. Lastly, there may be some species differences
that prevent the long-term effects of noggin in BVSMCs.
Nevertheless, our results indicate the importance of both
RUNX2 and BMP-2 in the regulation of calcification in
BVSMCs. It is likely that both RUNX2 and BMP-2 may
be more critical in the initiation of osteoblast-like cell
phenotypic change of uremic-serum-treated BVSMCs, but
thereafter, other factors are as important in the continuation
of calcification.
The synergistic relationship of RUNX2 and BMP-2 is not
surprising, as multiple studies have demonstrated that the
two osteo-inductive factors work in concert. Cells derived
from calvariae of RUNX2/ mice still synthesize osteo-
calcin in response to BMP-2, but at levels less than in cells
from wild-type embryos.14 Yang et al.42 found that over-
expression of BMP-2 or RUNX2 alone in C3H10T1/2
mesenchymal cells modestly induced ALP activity, osteo-
calcin expression, and mineralization. However, cotransfection
of cells with both BMP-2 and RUNX2 dramatically increased
ALP activity, osteocalcin expression, and mineralization over
levels in cells incubated with either factor alone.42 BMP-2 also
activates another transcription factor Msx2, which, in turn,
upregulates osterix, a global transcriptional regulator of
mineralization and osteoblast differentiation via a RUNX2-
independent signaling mechanism.43 Msx2 is upregulated in
areas of calcification of LDL/ mice fed on a high-fat
diet,44 and Msx2 expression has also been observed in human
atherosclerotic calcification.20 These results indicate that
vascular calcification of BVSMCs, similar to osteoblasts, is
a very complex and regulated process with a complex
interaction of multiple transcription factors.
In conclusion, this study demonstrated that RUNX2
transcriptional activity and cAMP/PKA are critical for the
initiation of uremic serum-induced phenotypic change of
BVSMCs to osteoblast-like cells. In addition, BMP-2 plays an
important regulatory role in uremic serum-induced RUNX2
expression and calcification in BVSMCs. Thus, both RUNX2
and BMP-2, along with other uremic toxins, work in concert
to regulate both desirable ossification in bones and undesir-
able ossification in arteries.
MATERIALS AND METHODS
Cell culture
BVSMCs were isolated from bovine thoracic aorta and cultured as
described previously.19,21 The serum used in experiments was either
fetal bovine serum (Sigma, St Louis, MO, USA), pooled uremic
serum from patients undergoing hemodialysis without residual
renal function (¼ uremic serum), or pooled serum from age-
matched healthy controls (¼ normal serum) collected as described
previously.19,21 For some experiments, cultures were treated with
specific inhibitors of PKA (KT5720, Calbiochem, San Diego, CA,
USA), cAMP production (SQ22536, Calbiochem, San Diego, CA,
USA), or PKC (GF10923X, Calbiochem) for 48 or 72 h. To
determine the involvement of BMPs, cultures were treated with or
without noggin, a BMP inhibitor, for 48 h (R&D Systems,
Minneapolis, MN, USA). To induce calcification, BVSMCs were
treated with 10 mmol/l b-glycerophosphate, 107 mol/l insulin, and
50 mg/ml ascorbic acid in the presence of 15% serum.8 To determine
the role of BMP-2 in calcification of BVSMCs, cells were treated with
calcification media in the presence or absence of 500 ng/ml
recombinant human BMP-2 (R&D Systems).
Transfection
BVSMCs were seeded at 2.2 105 cells/well in six-well culture plates
and transiently transfected with Lipofectamine (Invitrogen Inc.,
Carlsbad, CA, USA) after 24 h. RUNX2 DNA-binding domain
(DRUNX2) in pEFBOS expression vector (kindly provided by Dr
Gerard Karsenty, Baylor College of Medicine) was used in the
experiment. Ducy et al.22 have demonstrated that this DRUNX2
construct failed to transactivate a reporter vector containing six OSE
elements, the RUNX2-binding sites in COS cells that do not express
any RUNX2 genes. In DNA cotransfection experiments performed
in ROS17/2.8 osteoblastic cells that do express RUNX2, increasing
amount of DRUNX2 dramatically decreased osteocalcin promoter
activity.45 Each transfection contained 1 mg of DRUNX2 plus 0.2mg
of pSV-b-galactosidase control vector (Promega, Madison, WI,
USA). Control pEFBOS vector (a gift of Dr Kosei Ito, Institute of
Molecular and Cell Biology, Singapore) was also used as a negative
DNA transfection control. After 3 h of transfection, cells were
incubated with growth medium containing either 10% normal or
uremic serum for 72 h. b-Galactosidase activity present in each
lysate, measured by b-galactosidase enzyme assay system (Promega),
was used to standardize the transfection efficiency between different
experiments.
Reverse transcription-polymerase chain reaction
Reverse transcription-polymerase chain reaction (RT-PCR) was
performed using Titan one tube RT-PCR-kit (Roche Diagnostics,
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Indianapolis, IN, USA) as described previously.19 The sense primer
for RUNX2 was 50-CCGCACGACAACCGCACC-30 and the RUNX2
antisense primer was 50-CGCTCCGGCCCACAAATC-30. The RT-
PCR products were resolved on a 1.5% agarose gel and visualized by
ethidium bromide staining. The housekeeping gene b-actin was used
as an internal control. The band density was analyzed by scanning
densitometry (Quantity One, Bio-Rad, Richmond, CA, USA).
ALP assay
Cellular proteins were solubilized with 1% Triton X-100 in 0.9%
NaCl and centrifuged. Supernatants were assayed for ALP activity
(Pointe Scientific, Canton, MI, USA). One unit was defined as the
activity producing 1 nmol of p-nitrophenol for 30 min. Protein
concentrations were determined with a Bio-Rad protein assay kit
(Bio-Rad), and ALP activity was normalized to cellular protein
content.
Western blot analysis
Western blotting was performed as described previously.21 The blots
were incubated with rabbit antibodies against osteocalcin (LF-32,
1:1000; gift of Dr Larry Fisher, National Institute of Health)
overnight at 41C followed by incubating with peroxidase-conjugated
secondary antibody (1:5000 dilution). Immunodetection was with
the Enhanced Chemiluminescence Kit (Amersham, Piscataway, NJ,
USA). The band intensity was analyzed by scanning densitometry
(Quantity One, Bio-Rad, Richmond, CA, USA).
Calcification assay
BVSMCs were incubated in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum until confluent (¼ day 0 of
calcification assay). At each time point thereafter, BVSMCs were
decalcified with 0.6 N HCl for 24 h. The calcium content of HCl
supernatants was determined colorimetrically by the o-cresolphtha-
lein complex one method (Calcium kit; Pointe Scientific) as
described previously21 and normalized to protein content.
BMP-2 enzyme-linked immunosorbent assay
Before (pre) and after (post) cell culture incubation, conditioned
media from BVSMC cultures, or normal or uremic pooled sera, were
collected and centrifuged, and 50 ml used to measure BMP-2
concentrations using the Quantikine BMP-2 Immunoassay kit
(R&D systems).
Statistical analysis
All experiments were conducted at least three to four times, with
triplicate cultures in each experiment averaged for the final
statistical analysis. The difference of ALP activity, osteocalcin
expression, BMP-2 concentrations, and RUNX2/b-actin ratio in
response to various treatments was compared by analysis of variance
with Fisher’s post hoc analysis. Differences in calcification over time
and between groups were analyzed with two-way analysis of variance
with Fisher’s post hoc analysis. The results are expressed as
mean7s.d., with Po0.05 considered significant (StatView, SAS
Institute Inc., Cary, NC, USA).
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